Sinha Suhani, Garg Vandana, Thapa Sonia, Singh Shashank, Chauhan Mahima, Dutt Rohit, Singh Rahul Pratap
Department of Pharmacy, School of Medical and Allied Sciences, G. D. Goenka University, Gurugram, Haryana, India.
Guru Teg Bahadur Hospital, GTB Enclave, Dilshad Garden, New Delhi, Delhi, India.
Drug Dev Ind Pharm. 2022 Jul;48(7):279-291. doi: 10.1080/03639045.2022.2108829. Epub 2022 Aug 10.
The main objective of this study was to develop the orodispersity film containing chitosan-alginate nanoparticles to improve dissolution profile, therapeutic effect with improved bioavailability of empagliflozin through oral route noninvasively for further cytotoxicity study.
The nanoparticles were developed through two-step mechanisms ionotropic pre-gelation and polyelectrolyte complexation methods. The prepared nanoparticles were added to a polymer matrix containing hypromellose, polyvinyl alcohol, and maltodextrin and cast to rapidly dissolving thin film by solvent casting method.
The physicochemical characteristics of empagliflozin in the orodispersible film were most favorable for further studies. This formulation has achieved a higher permeability (7.2-fold) as compared to the reference drug product (Jardiance) after 45 min. pharmacokinetic studies in Wistar rats have revealed that chitosan-alginate empagliflozin nanoparticles in the orodispersible film were 1.18-fold more bioavailable in comparison to free empagliflozin in orodispersible film. The observed for the empagliflozin-loaded orodispersible film was 15.42 ± 5.13 μg/mL in comparison to 18.21 ± 5.53 μg/mL for empagliflozin nanoparticle-containing orodispersible film and 12.19 ± 6.71 μg/mL for freed rug suspension. The tand AUC values for chitosan-alginate nanoparticles of empagliflozin in the orodispersible film were found1.4-fold more than empagliflozin loaded orodispersible film (without nanoparticles). The cytotoxicity study has shown that chitosan-alginate nanoparticles of empagliflozin in orodispersible film achieved a 2.5-fold higher cytotoxic effect than free empagliflozin in orodispersible film in A549lung cancer cells.
This study provides evidence that chitosan-alginate nanoparticles of empagliflozin in orodispersible film can be an effective drug carrier system to improve sustained effect with better bioavailability of poorly water-soluble drug.
本研究的主要目的是开发含壳聚糖-海藻酸盐纳米颗粒的口腔崩解膜,以改善恩格列净的溶出曲线,通过口服途径无创提高其治疗效果和生物利用度,用于进一步的细胞毒性研究。
通过离子型预凝胶化和聚电解质络合两步机制制备纳米颗粒。将制备的纳米颗粒加入含有羟丙甲纤维素、聚乙烯醇和麦芽糊精的聚合物基质中,采用溶剂浇铸法浇铸成快速溶解的薄膜。
恩格列净口腔崩解膜的理化特性最有利于进一步研究。与参比药品(捷诺达)相比,该制剂在45分钟后具有更高的渗透率(7.2倍)。在Wistar大鼠中的药代动力学研究表明,与口腔崩解膜中的游离恩格列净相比,口腔崩解膜中的壳聚糖-海藻酸盐恩格列净纳米颗粒的生物利用度高1.18倍。载恩格列净口腔崩解膜的观察值为15.42±5.13μg/mL,含恩格列净纳米颗粒的口腔崩解膜为18.21±5.53μg/mL,游离药物混悬液为12.19±6.71μg/mL。口腔崩解膜中恩格列净壳聚糖-海藻酸盐纳米颗粒的tand AUC值比载恩格列净口腔崩解膜(无纳米颗粒)高1.4倍。细胞毒性研究表明,口腔崩解膜中恩格列净壳聚糖-海藻酸盐纳米颗粒在A549肺癌细胞中的细胞毒性比口腔崩解膜中的游离恩格列净高2.5倍。
本研究提供了证据,表明口腔崩解膜中恩格列净壳聚糖-海藻酸盐纳米颗粒可以作为一种有效的药物载体系统,以改善难溶性药物的持续效果和生物利用度。